[1]
|
See, J., Zhang, X., Eraydin, N., et al. (2004) Oligodendrocyte Maturation Is Inhibited by Bone Morphogenetic Protein. Molecular and Cellular Neurosciences, 26, 481-492. https://doi.org/10.1016/j.mcn.2004.04.004
|
[2]
|
Armangue, T., Olivé-Cirera, G., Martínez-Hernandez, E., et al. (2020) Associations of Paediatric Demyelinating and Encephalitic Syn-dromes with Myelin Oligodendrocyte Glycoprotein Antibodies: A Multicentre Observational Study. The Lancet Neurol-ogy, 19, 234-246. https://doi.org/10.1016/S1474-4422(19)30488-0
|
[3]
|
Boesen, M.S., Jensen, P.E.H., Born, A.P., et al. (2019) Incidence of Pediatric Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in Denmark 2008-2018: A Nationwide, Population-Based Cohort Study. Multiple Sclero-sis and Related Disorders, 33, 162-167.
https://doi.org/10.1016/j.msard.2019.06.002
|
[4]
|
Jarius, S., Ruprecht, K., Kleiter, I., et al. (2016) MOG-IgG in NMO and Related Disorders: A Multicenter Study of 50 Patients. Part 2: Epidemiology, Clinical Presentation, Radiolog-ical and Laboratory Features, Treatment Responses, and Long-Term Outcome. Journal of Neuroinflammation, 13, Article No. 280. https://doi.org/10.1186/s12974-016-0718-0
|
[5]
|
Jurynczyk, M., Messina, S., Woodhall, M.R., et al. (2017) Clinical Presentation and Prognosis in MOG-Antibody Disease: A UK Study. Brain, 140, 3128-3138. https://doi.org/10.1093/brain/awx276
|
[6]
|
Mao, L., Yang, L., Kessi, M., et al. (2019) Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Diseases in Children in Central South China: Clinical Features, Treatments, Influencing Factors, and Outcomes. Frontiers in Neurology, 10, Article No. 868. https://doi.org/10.3389/fneur.2019.00868
|
[7]
|
Weinshenker, B.G. and Wingerchuk, D.M. (2017) Neuromyelitis Spectrum Disorders. Mayo Clinic Proceedings, 92, 663-679. https://doi.org/10.1016/j.mayocp.2016.12.014
|
[8]
|
Akaishi, T., Takahashi, T., Misu, T., et al. (2020) Progressive Patterns of Neurological Disability in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders. Scientific Reports, 10, Article No. 13890.
https://doi.org/10.1038/s41598-020-70919-w
|
[9]
|
Jarius, S., Aktas, O., Ayzenberg, I., et al. (2023) Update on the Diagnosis and Treatment of Neuromyelits Optica Spectrum Disorders (NMOSD)—Revised Recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and Differential Diagnosis. Journal of Neurology, 270, 3341-3368.
https://doi.org/10.1007/s00415-023-11634-0
|
[10]
|
Bruijstens, A.L., Wendel, E.M., Lechner, C., et al. (2020) E.U. Paediatric MOG Consortium Consensus: Part 5. Treatment of Paediatric Myelin Oligodendrocyte Glycoprotein Anti-body-Associated Disorders. European Journal of Paediatric Neurology: EJPN: Official Journal of the European Paedi-atric Neurology Society, 29, 41-53.
https://doi.org/10.1016/j.ejpn.2020.10.005
|
[11]
|
Whittam, D.H., Karthikeayan, V., Gibbons, E., et al. (2020) Treat-ment of MOG Antibody Associated Disorders: Results of an International Survey. Journal of Neurology, 267, 3565-3577. https://doi.org/10.1007/s00415-020-10026-y
|
[12]
|
Bruijstens, A.L., Lechner, C., Flet-Berliac, L., et al. (2020) E.U. Paediatric MOG Consortium Consensus: Part 1. Classification of Clinical Phenotypes of Paediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders. European Journal of Paediatric Neurology: EJPN: Offi-cial Journal of the European Paediatric Neurology Society, 29, 2-13. https://doi.org/10.1016/j.ejpn.2020.10.006
|
[13]
|
Wendel, E.M., Thonke, H.S., Bertolini, A., et al. (2022) Temporal Dynamics of MOG Antibodies in Children with Acquired Demyelinating Syndrome. Neurology Neuroimmunology & Neuroinflammation, 9, e200035.
|
[14]
|
Hacohen, Y., Wong, Y.Y., Lechner, C., et al. (2018) Disease Course and Treat-ment Responses in Children with Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. JAMA Neurology, 75, 478-487.
https://doi.org/10.1001/jamaneurol.2017.4601
|
[15]
|
Oliveira, L.M., Apóstolos-Pereira, S.L., Pitombeira, M.S., et al. (2019) Persistent MOG-IgG Positivity Is a Predictor of Recurrence in MOG-IgG-Associated Optic Neuritis, Encephalitis and Myelitis. Multiple Sclerosis (Houndmills, Basingstoke, England), 25, 1907-1914. https://doi.org/10.1177/1352458518811597
|
[16]
|
Hennes, E.M., Baumann, M., Schanda, K., et al. (2017) Prognos-tic Relevance of MOG Antibodies in Children with an Acquired Demyelinating Syndrome. Neurology, 89, 900-908. https://doi.org/10.1212/WNL.0000000000004312
|
[17]
|
Cobo-Calvo, A., Ruiz, A., Rollot, F., et al. (2021) Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Annals of Neurology, 89, 30-41.
https://doi.org/10.1002/ana.25909
|
[18]
|
López-Chiriboga, A.S., Majed, M., Fryer, J., et al. (2018) Association of MOG-IgG Serostatus with Relapse after Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders. JAMA Neurology, 75, 1355-1363. https://doi.org/10.1001/jamaneurol.2018.1814
|
[19]
|
Gastaldi, M., Foiadelli, T., Greco, G., et al. (2023) Prognostic Relevance of Quantitative and Longitudinal MOG Antibody Testing in Patients with MOGAD: A Multicentre Retrospec-tive Study. Journal of Neurology, Neurosurgery, and Psychiatry, 94, 201-210. https://doi.org/10.1136/jnnp-2022-330237
|
[20]
|
Duignan, S., Wright, S., Rossor, T., et al. (2018) Myelin Oli-godendrocyte Glycoprotein and Aquaporin-4 Antibodies Are Highly Specific in Children with Acquired Demyelinating Syndromes. Developmental Medicine and Child Neurology, 60, 958-962. https://doi.org/10.1111/dmcn.13703
|
[21]
|
Mariano, R., Messina, S., Roca-Fernandez, A., et al. (2021) Quantitative Spinal Cord MRI in MOG-Antibody Disease, Neuromyelitis Optica and Multiple Sclerosis. Brain, 144, 198-212. https://doi.org/10.1093/brain/awaa347
|
[22]
|
Cortese, R., Battaglini, M., Prados, F., et al. (2023) Clinical and MRI Measures to Identify Non-Acute MOG-Antibody Disease in Adults. Brain, 146, 2489-2501. https://doi.org/10.1093/brain/awaa347
|
[23]
|
Fernandez-Carbonell, C., Vargas-Lowy, D., Musallam, A., et al. (2016) Clinical and MRI Phenotype of Children with MOG Antibodies. Multiple Sclerosis (Houndmills, Basingstoke, England), 22, 174-184.
https://doi.org/10.1177/1352458515587751
|
[24]
|
Solomon, A.J., Arrambide, G., Brownlee, W.J., et al. (2023) Dif-ferential Diagnosis of Suspected Multiple Sclerosis: An Updated Consensus Approach. The Lancet Neurology, 22, 750-768.
https://doi.org/10.1016/S1474-4422(23)00148-5
|
[25]
|
Camera, V., Holm-Mercer, L., Ali, A.A.H., et al. (2021) Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder. JAMA Network Open, 4, E2137833. https://doi.org/10.1001/jamanetworkopen.2021.37833
|
[26]
|
Fadda, G., Banwell, B., Waters, P., et al. (2021) Silent New Brain MRI Lesions in Children with MOG-Antibody Associated Disease. Annals of Neurology, 89, 408-413. https://doi.org/10.1002/ana.25957
|
[27]
|
Hacohen, Y., Rossor, T., Mankad, K., et al. (2018) “Leukodystrophy-Like” Phenotype in Children with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. Developmental Medi-cine and Child Neurology, 60, 417-423.
https://doi.org/10.1111/dmcn.13649
|
[28]
|
Bennett, J.L., Nickerson, M., Costello, F., et al. (2015) Re-Evaluating the Treatment of Acute Optic Neuritis. Journal of Neurology, Neurosurgery, and Psychiatry, 86, 799-808. https://doi.org/10.1136/jnnp-2014-308185
|
[29]
|
Oertel, F.C., Outteryck, O., Knier, B., et al. (2019) Optical Coher-ence Tomography in Myelin-Oligodendrocyte-Gly- coprotein Antibody-Seropositive Patients: A Longitudinal Study. Journal of Neuroinflammation, 16, Article No. 154. https://doi.org/10.1186/s12974-019-1521-5
|
[30]
|
Eyre, M., Hameed, A., Wright, S., et al. (2018) Retinal Nerve Fibre Layer Thinning Is Associated with Worse Visual Outcome af-ter Optic Neuritis in Children with a Relapsing Demyelinating Syndrome. Developmental Medicine and Child Neurology, 60, 1244-1250. https://doi.org/10.1111/dmcn.13757
|
[31]
|
Havla, J., Pakeerathan, T., Schwake, C., et al. (2021) Age-Dependent Favorable Visual Recovery despite Significant Retinal Atrophy in Pediatric MOGAD: How Much Reti-na Do You Really Need to See Well? Journal of Neuroinflammation, 18, Article No 121. https://doi.org/10.1186/s12974-021-02160-9
|
[32]
|
Marignier, R., Hacohen, Y., Cobo-Calvo, A., et al. (2021) Mye-lin-Oligodendrocyte Glycoprotein Antibody-Associated Disease. The Lancet Neurology, 20, 762-772. https://doi.org/10.1016/S1474-4422(21)00218-0
|
[33]
|
Ramanathan, S., Mohammad, S., Tantsis, E., et al. (2018) Clinical Course, Therapeutic Responses and Outcomes in Relapsing MOG Antibody-Associated Demyelination. Journal of Neurology, Neurosurgery, and Psychiatry, 89, 127-137. https://doi.org/10.1136/jnnp-2017-316880
|
[34]
|
Nosadini, M., Eyre, M., Giacomini, T., et al. (2023) Early Immu-notherapy and Longer Corticosteroid Treatment Are Associated with Lower Risk of Relapsing Disease Course in Pediat-ric MOGAD. Neurology(R) Neuroimmunology & Neuroinflammation, 10, e200065. https://doi.org/10.1212/NXI.0000000000200065
|
[35]
|
Satukijchai, C., Mariano, R., Messina, S., et al. (2022) Fac-tors Associated with Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in the United Kingdom. JAMA Network Open, 5, E2142780.
https://doi.org/10.1001/jamanetworkopen.2021.42780
|
[36]
|
Eftimov, F., Vermeulen, M., Van Doorn, P.A., et al. (2012) Long-Term Remission of CIDP after Pulsed Dexamethasone or Short-Term Prednisolone Treatment. Neurology, 78, 1079-1084.
https://doi.org/10.1212/WNL.0b013e31824e8f84
|
[37]
|
Ratzer, R., Iversen, P., Börnsen, L., et al. (2016) Monthly Oral Methylprednisolone Pulse Treatment in Progressive Multiple Sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England), 22, 926-934.
https://doi.org/10.1177/1352458515605908
|
[38]
|
Van Schaik, I.N., Eftimov, F., Van Doorn, P.A., et al. (2010) Pulsed High-Dose Dexamethasone versus Standard Prednisolone Treatment for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (PREDICT Study): A Double-Blind, Randomised, Controlled Trial. The Lancet Neurology, 9, 245-253. https://doi.org/10.1016/S1474-4422(10)70021-1
|
[39]
|
Chen, J.J., Flanagan, E.P., Bhatti, M.T., et al. (2020) Steroid-Sparing Maintenance Immunotherapy for MOG-IgG Associated Disorder. Neurology, 95, E111-E120. https://doi.org/10.1212/WNL.0000000000009758
|
[40]
|
Cobo-Calvo, A., Sepúlveda, M., Rollot, F., et al. (2019) Evaluation of Treatment Response in Adults with Relapsing MOG-Ab-Associated Disease. Journal of Neuroinflamma-tion, 16, Article No. 134.
https://doi.org/10.1186/s12974-019-1525-1
|
[41]
|
Li, S., Ren, H., Xu, Y., et al. (2020) Long-Term Efficacy of My-cophenolate Mofetil in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders: A Prospective Study. Neurology(R) Neuroimmunology & Neuroinflammation, 7, e705. https://doi.org/10.1212/NXI.0000000000000705
|
[42]
|
Zhou, J., Lu, X., Zhang, Y., et al. (2019) Follow-Up Study on Chinese Children with Relapsing MOG-IgG-Associated Central Nervous System Demyelination. Multiple Sclerosis and Related Disorders, 28, 4-10.
https://doi.org/10.1016/j.msard.2018.12.001
|
[43]
|
Whittam, D.H., Cobo-Calvo, A., Lopez-Chiriboga, A.S., et al. (2020) Treatment of MOG-IgG-Associated Disorder with Rituximab: An International Study of 121 Patients. Multiple Sclerosis and Related Disorders, 44, Article ID: 102251. https://doi.org/10.1016/j.msard.2020.102251
|
[44]
|
Albassam, F., Longoni, G., Yea, C., et al. (2020) Rituximab in Children with Myelin Oligodendrocyte Glycoprotein Antibody and Relapsing Neuroinflammatory Disease. Develop-mental Medicine and Child Neurology, 62, 390-395.
https://doi.org/10.1016/j.msard.2020.102251
|
[45]
|
Dale, R.C., Brilot, F., Duffy, L.V., et al. (2014) Utility and Safety of Rituximab in Pediatric Autoimmune and Inflammatory CNS Disease. Neurology, 83, 142-150. https://doi.org/10.1212/WNL.0000000000000570
|
[46]
|
Avouac, A., Maarouf, A., Stellmann, J.P., et al. (2021) Rituximab-Induced Hypogammaglobulinemia and Infections in AQP4 and MOG Antibody-Associated Diseases. Neu-rology(R) Neuroimmunology & Neuroinflammation, 8, e1179.
https://doi.org/10.1212/NXI.0000000000000977
|
[47]
|
Lai, Q.L., Zhang, Y.X., Cai, M.T., et al. (2021) Efficacy and Safety of Immunosuppressive Therapy in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Sys-tematic Review and Meta-Analysis. Therapeutic Advances in Neurological Disorders, 14. https://doi.org/10.1177/17562864211054157
|
[48]
|
Lünemann, J.D., Nimmerjahn, F. and Dalakas, M.C. (2015) In-travenous Immunoglobulin in Neurology—Mode of Action and Clinical Efficacy. Nature Reviews Neurology, 11, 80-89. https://doi.org/10.1038/nrneurol.2014.253
|
[49]
|
Sotirchos, E.S., Vasileiou, E.S., Salky, R., et al. (2022) Treatment of Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease with Subcutaneous Immune Globulin. Multiple Sclerosis and Related Disorders, 57, Article ID: 103462. https://doi.org/10.1016/j.msard.2021.103462
|
[50]
|
Lennon, V.A., Kryzer, T.J., Pittock, S.J., et al. (2005) IgG Marker of Optic-Spinal Multiple Sclerosis Binds to the Aquaporin-4 Water Channel. The Journal of Experimental Medi-cine, 202, 473-477. https://doi.org/10.1084/jem.20050304
|
[51]
|
Phuan, P.W., Ratelade, J., Rossi, A., et al. (2012) Complement-Dependent Cytotoxicity in Neuromyelitis Optica Requires Aquaporin-4 Protein Assembly in Orthogonal Arrays. The Journal of Biological Chemistry, 287, 13829-13839.
https://doi.org/10.1074/jbc.M112.344325
|
[52]
|
Soltys, J., Liu, Y., Ritchie, A., et al. (2019) Membrane Assembly of Aquaporin-4 Autoantibodies Regulates Classical Complement Activation in Neuromyelitis Optica. The Journal of Clini-cal Investigation, 129, 2000-2013.
https://doi.org/10.1172/JCI122942
|
[53]
|
Takai, Y., Misu, T., Suzuki, H., et al. (2021) Staging of Astrocytopathy and Complement Activation in Neuromyelitis Optica Spectrum Disorders. Brain, 144, 2401-2415. https://doi.org/10.1093/brain/awab102
|
[54]
|
Stathopoulos, P. and Dalakas, M.C. (2022) The Role of Complement and Complement Therapeutics in Neuromyelitis Optica Spectrum Disorders. Expert Review of Clinical Immunology, 18, 933-945.
https://doi.org/10.1080/1744666X.2022.2105205
|
[55]
|
Hiya, S., Yoshimura, H. and Kawamoto, M. (2023) Suc-cessful Treatment with Subcutaneous Ofatumumab in an Adolescent Patient with Refractory Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G-Associated Disease (MOGAD). eNeurologicalSci, 31, Article ID: 100461. https://doi.org/10.1016/j.ensci.2023.100461
|
[56]
|
Zhang, R., Wang, L., Tao, Y., et al. (2023) The Case Report of MOG and NMDAR IgG Double Positive Encephalitis Treated with Subcutaneous Ofatumumab. Frontiers in Immunol-ogy, 14, Article ID: 1183488.
https://doi.org/10.3389/fimmu.2023.1183488
|
[57]
|
Okuda, Y., Sakoda, S., Fujimura, H., et al. (1999) IL-6 Plays A Crucial Role in the Induction Phase of Myelin Oligodendrocyte Glucoprotein 35-55 Induced Experimental Autoimmune Encephalomyelitis. Journal of Neuroimmunology, 101, 188-196. https://doi.org/10.1016/S0165-5728(99)00139-3
|
[58]
|
Kaneko, K., Sato, D.K., Nakashima, I., et al. (2018) CSF Cytokine Profile in MOG-IgG+ Neurological Disease Is Similar to AQP4-IgG+ NMOSD but Distinct from MS: A Cross-Sectional Study and Potential Therapeutic Implications. Journal of Neurology, Neurosurgery, and Psychiatry, 89, 927-936. https://doi.org/10.1136/jnnp-2018-317969
|
[59]
|
Kothur, K., Wienholt, L., Tantsis, E.M., et al. (2016) B Cell, Th17, and Neutrophil Related Cerebrospinal Fluid Cytokine/Chemokines Are Elevated in MOG Antibody Associ-ated Demyelination. PLOS ONE, 11, e0149411.
https://doi.org/10.1371/journal.pone.0149411
|
[60]
|
Novi, G., Gastaldi, M., Franciotta, D., et al. (2019) Tocilizumab in MOG-Antibody Spectrum Disorder: A Case Report. Multiple Sclerosis and Related Disorders, 27, 312-314. https://doi.org/10.1016/j.msard.2018.11.012
|
[61]
|
Hayward-Koennecke, H., Reindl, M., Martin, R., et al. (2019) Tocilizumab Treatment in Severe Recurrent Anti-MOG- Associated Optic Neuritis. Neurology, 92, 765-767. https://doi.org/10.1212/WNL.0000000000007312
|
[62]
|
Elsbernd, P.M., Hoffman, W.R., Carter, J.L., et al. (2021) Interleukin-6 Inhibition with Tocilizumab for Relapsing MOG-IgG Associated Disorder (MOGAD): A Case-Series and Review. Multiple Sclerosis and Related Disorders, 48, Article ID: 102696. https://doi.org/10.1016/j.msard.2020.102696
|
[63]
|
Rigal, J., Pugnet, G., Ciron, J., et al. (2020) Off-Label Use of Tocilizumab in Neuromyelitis Optica Spectrum Disorders and MOG-Antibody-Associated Diseases: A Case-Series. Multiple Sclerosis and Related Disorders, 46, Article ID: 102483. https://doi.org/10.1016/j.msard.2020.102483
|
[64]
|
Mader, S., Ho, S., Wong, H.K., et al. (2023) Dissection of Complement and Fc-Receptor-Mediated Pathomechanisms of Autoantibodies to Myelin Oligodendrocyte Glycoprotein. Proceedings of the National Academy of Sciences of the United States of America, 120, E2300648120. https://doi.org/10.1073/pnas.2300648120
|
[65]
|
Ruck, T., Nimmerjahn, F., Wiendl, H., et al. (2022) Next-Generation Antibody-Based Therapies in Neurology. Brain, 145, 1229-1241. https://doi.org/10.1093/brain/awab465
|